ARCT vs. NRIX, STOK, RCUS, LGND, STTK, ALKS, PRGO, CRNX, AXSM, and CORT
Should you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Nurix Therapeutics (NRIX), Stoke Therapeutics (STOK), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), Shattuck Labs (STTK), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Nurix Therapeutics (NASDAQ:NRIX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
Arcturus Therapeutics has a net margin of -81.59% compared to Arcturus Therapeutics' net margin of -178.93%. Nurix Therapeutics' return on equity of -37.61% beat Arcturus Therapeutics' return on equity.
Arcturus Therapeutics has higher revenue and earnings than Nurix Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics received 378 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Nurix Therapeutics an outperform vote while only 65.44% of users gave Arcturus Therapeutics an outperform vote.
In the previous week, Arcturus Therapeutics had 3 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 6 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.06 beat Arcturus Therapeutics' score of 0.59 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.
Nurix Therapeutics has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nurix Therapeutics presently has a consensus price target of $21.88, indicating a potential upside of 38.89%. Arcturus Therapeutics has a consensus price target of $64.86, indicating a potential upside of 67.11%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Nurix Therapeutics.
Summary
Arcturus Therapeutics beats Nurix Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Arcturus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcturus Therapeutics Competitors List
Related Companies and Tools
